Type1Screen: How Early Detection Screening Programs Are Evolving

A major Type 1 diabetes screening initiative is shifting toward at-home testing methods and expanding who can participate. Here's what researchers are learning about making early detection more accessible.

cureresearchclinical trial

Key takeaways

Type1Screen, launched in 2019, uses blood tests to identify people at risk for Type 1 diabetes before symptoms appear
The program recently moved from clinic-based blood collection to at-home sampling, paired with a newer PCR-based antibody test
Researchers are expanding eligibility to include people over age 2, rather than limiting to specific age groups
A major challenge for screening programs is reaching people who could benefit—media outreach and direct communication appear more effective than relying on clinician referrals alone
Adequate funding and resources remain critical bottlenecks in expanding screening efforts

What Type1Screen Does

Type1Screen is a research program that tests people for autoantibodies—markers that suggest the immune system is beginning to attack insulin-producing cells. Finding these antibodies early, before Type 1 diabetes develops, opens a window for potential interventions being tested in clinical trials.

The program launched in 2019, supported by JDRF, in response to significant funding reductions for other screening efforts. Its goal is to identify at-risk individuals in the community, not just in clinic settings.

A Shift Toward Home-Based Testing

Until recently, Type1Screen collected blood samples at medical facilities and sent them to a lab in Melbourne for analysis. About a year ago, the program transitioned to at-home blood collection, which participants can do themselves.

The laboratory method also changed. Type1Screen now uses a PCR-based antibody assay—a molecular technique that researchers report has produced 'very good results' compared to the earlier standard approach. This combination of home sampling and improved testing may make screening more accessible and practical for more people.

Who Can Participate Is Expanding

Originally, screening programs often focused on specific age groups. Type1Screen has moved away from age restrictions, now welcoming participants over age 2. This broader approach reflects an understanding that Type 1 diabetes can develop across a wide age range, and that early detection should be available to more people.

The Challenge: Reaching People Who Need It

While the science and logistics of screening are improving, researchers face a significant hurdle: getting the word out. Type1Screen leaders emphasize that media coverage and direct outreach to affected families are far more effective at driving participation than expecting doctors to refer patients.

Many clinicians, the researchers note, still lag in offering screening to their patients—even those who would be eligible. This suggests that education and communication, not just availability of tests, are key to expanding who gets screened.

Evidence label

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.